History

1997

Start of publicly sponsored BMBF-Project „Development of a novel wound dressing for burns” at Europe’s leading institute for textile research ITV Denkendorf.

2001

Foundation of Polymedics Innovations GmbH by the five leading scientists who developed SUPRATHEL^® and other tissue engineering technologies. 

2004

CE mark and launch of SUPRATHEL^® in Germany and Austria.

2004-2009

International Expansion and regulatory approvals in Switzerland, Nordics, UK,  Italy, Turkey, South Africa, Mexico, Pakistan, Australia.

2009

US – FDA 510K approval.

2010

KFDA approval in Korea.
Inauguration of state of the art in-house production in Denkendorf, Germany.

2015

Foundation of US subsidiary Polymedics Innovations Inc.
Today PMI develops and manufactures new technologies for the wound care sector in Denkendorf and markets its products in 30 countries around the world. 

2016

Opening of US subsidiarity in Woodstock, Georgia.

2017

SUPRA SDRM® 510k certification in the United States.

2019

SUPRA SDRM® product approval in the European Union.

Cooperation with PolyNovo Biomaterials Pty Ltd. for the distribution of NovoSorb® BTM in the DACH (Germany, Austria, Switzerland) region.

2020

Christian Planck appointed as Co-CEO of PolyMedics Innovations GmbH alongside Prof. Dr. Heinrich Planck.

PMI expands the distribution of NovoSorb® BTM to Benelux and Sweden.

2021

Product launch of the novel synthetic guided wound closure matrix SUPRA SDRM® for difficult to heal wounds.